The Obesity Drug That Rivals Surgery In the TRIUMPH-4 trial, retatrutide helped people with obesity lose an average of: 23.7% of their body weight when counting all participants, including those who discontinued treatment 28.7% weight loss among people who stayed on the highest dose throughout the 68-week study Dr Caroline Apovian from Brigham and Womens Hospital called the results incredible, noting that this is the first drug to show weight loss comparable to weight-loss surgery
In clinical trials of semaglutide injection for weight management, acute pancreatitis was confirmed by adjudication in 4 semaglutide-treated patients (0.2 cases per 100 patient-years) versus 1 in placebo-treated patients (less than 0.1 cases per 100 patient-years)
doi: 10.1016/j.cell.2006.10.018
Products marketed as personalized blends with added vitamins or other ingredients, without a clear clinical rationale, are often designed to tout those additions to sidestep regulations rather than to benefit the patient
This could involve temporarily reducing the dose, switching to a different GLP-1 receptor agonist with a different pharmacokinetic profile, or investigating whether concurrent medications contribute to tiredness
